{
    "ticker": "ORGO",
    "name": "Organogenesis Holdings Inc.",
    "description": "Organogenesis Holdings Inc. is a leading regenerative medicine company focused on developing and commercializing innovative products for the advanced wound care and surgical biologics markets. Founded in 1985 and headquartered in Canton, Massachusetts, Organogenesis has a long-standing commitment to improving patient outcomes through the development of groundbreaking cellular therapies. The company specializes in the manufacturing and distribution of a range of biologic products, including dermal grafts, amniotic membrane-based products, and other regenerative solutions that promote healing and tissue regeneration. Organogenesis is particularly known for its flagship products, such as Apligraf and Dermagraft, which are designed to treat complex wounds and support surgical procedures. The company's mission is to leverage its expertise in cell biology to enhance healing processes and provide healthcare professionals with effective tools to treat patients. With a robust pipeline of innovative products and a dedication to research and development, Organogenesis is positioned at the forefront of regenerative medicine, working to address unmet needs in patient care and improve the quality of life for individuals suffering from chronic wounds and surgical complications.",
    "industry": [
        "Biotechnology",
        "Medical Devices"
    ],
    "headquarters": "Canton, Massachusetts, USA",
    "founded": "1985",
    "website": "https://www.organogenesis.com",
    "ceo": "Gary S. Gillheeney",
    "social_media": {
        "twitter": "https://twitter.com/Organogenesis",
        "linkedin": "https://www.linkedin.com/company/organogenesis"
    },
    "investor_relations": "https://investors.organogenesis.com",
    "key_executives": [
        {
            "name": "Gary S. Gillheeney",
            "position": "CEO"
        },
        {
            "name": "Michael A. Henson",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Wound Care Products",
            "products": [
                "Apligraf",
                "Dermagraft"
            ]
        },
        {
            "category": "Surgical Biologics",
            "products": [
                "AmnioBand",
                "NeoCart"
            ]
        }
    ],
    "seo": {
        "meta_title": "Organogenesis Holdings Inc. | Regenerative Medicine Solutions",
        "meta_description": "Explore Organogenesis Holdings Inc., a leader in regenerative medicine focused on advanced wound care and surgical biologics. Discover innovative therapies and products.",
        "keywords": [
            "Organogenesis",
            "Regenerative Medicine",
            "Wound Care",
            "Biologics",
            "Apligraf",
            "Dermagraft"
        ]
    },
    "faq": [
        {
            "question": "What does Organogenesis specialize in?",
            "answer": "Organogenesis specializes in regenerative medicine, particularly in advanced wound care and surgical biologics."
        },
        {
            "question": "Who is the CEO of Organogenesis?",
            "answer": "Gary S. Gillheeney is the CEO of Organogenesis Holdings Inc."
        },
        {
            "question": "Where is Organogenesis headquartered?",
            "answer": "Organogenesis is headquartered in Canton, Massachusetts, USA."
        },
        {
            "question": "What are some of Organogenesis's main products?",
            "answer": "Some of Organogenesis's main products include Apligraf and Dermagraft."
        },
        {
            "question": "When was Organogenesis founded?",
            "answer": "Organogenesis was founded in 1985."
        }
    ],
    "competitors": [
        "AXGN",
        "AMRN",
        "ISRG",
        "CRMD"
    ],
    "related_stocks": [
        "MDT",
        "ZBH",
        "SYK",
        "ABT"
    ]
}